Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Carboplatin in Newly Diagnosed Intermediate- and High-Risk Rhabdomyosarcoma
NCT00077285Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2003
- Primary completion
- Oct 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and carboplatin in rhabdomyosarcoma (RMS) and undifferentiated sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Response rate at 2 years, Acute toxic effects at 2 years and 2 more. Started Oct 2003; status: active, not recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcarboplatin
03
Conditions
rhabdomyosarcoma (RMS)undifferentiated sarcoma
Beyond the preview
Go deeper on NCT00077285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077285.